Results 81 to 90 of about 112,464 (281)

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

, 2007
Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the ...
El Fassi, Daniel, Nielsen, Claus H, Hasselbalch, Hans C, Bonnema, Steen J, Hegedüs, Laszlo, Hasselbalch, Hans K, Bonnema, Steen Joop   +6 more
core   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source

Case Report: Successful treatment of steroid-refractory severe immunotherapy-induced pneumonitis with equine antithymocyte globulin

Frontiers in Oncology
Immune checkpoint inhibitors (ICI) have revolutionized melanoma treatment but are associated with autoimmune toxicities. Immunotherapy-induced pneumonitis (IIP) is a potentially fatal immune-related adverse event.
Thi Thao Vi Luong, Lindon Lin, John Coutsouvelis, John Coutsouvelis, Eli Dabscheck, Steven Ivulich, Hayley Burridge, Dominic Keating, Mark Shackleton, Mark Shackleton, Andrew Haydon, Miles C. Andrews, Miles C. Andrews   +12 more
doaj   +1 more source

Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature

, 2013
Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE).
Morris, SD, Hofmann, SC, Leandro, MJ, Isenberg, DA   +3 more
core  

Targeting METTL3 Attenuates Thyroid Inflammatory Injury by Restoring Th17/Treg Balance through a YTHDC2‐m6A‐Dependent KDR/VEGFA Loop

Advanced Science, EarlyView.
METTL3‐mediated m6A modification stabilizes KDR/Kdr mRNA through YTHDC2, amplifying the VEGFA‐KDR feedback loop and disturbing Th17/Treg balance. This pathway promotes persistent inflammation and tissue damage in patients with AIT, and inhibiting the METTL3‐KDR axis effectively disrupts this circuit, alleviating thyroid tissue injury and disease ...
Qingyi Hu, Huan Liu, Anwen Ren, Zimei Tang, Jie Tan, Wen Yang, Jie Ming, Tao Huang   +7 more
wiley   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

Advanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee, Jack Chun Hin Chen, Wai Wing Cheng, Kwan Yee Lau, Hiu Yee Kwan, Ngar‐Yun Ellen Poon, Hung‐Wing Li   +6 more
wiley   +1 more source

Accelerated in vivo proliferation of memory phenotype CD4+ T-cells in human HIV-1 infection irrespective of viral chemokine co-receptor tropism.

, 2013
CD4(+) T-cell loss is the hallmark of HIV-1 infection. CD4 counts fall more rapidly in advanced disease when CCR5-tropic viral strains tend to be replaced by X4-tropic viruses.
de Lara, C, Zhang Yan, Hegedus Andrea, Karoliina Laamanen, Derek Macallan, de Lara Catherine, Peter Beverley, Laamanen Karoliina, Catherine de Lara (339229), Karoliina Laamanen (233571), Yan Zhang (8098), Worth Andrew, Laamanen, K, Andrew Worth, Andrea Hegedus, Hegedus, A, Beverley Peter, Andrew Worth (404365), Worth, A, Zhang, Y, Macallan, D, Andrea Hegedus (404366), Peter Beverley (404367), Macallan Derek, Beverley, P, Yan Zhang, Catherine de Lara, Derek Macallan (404368)   +27 more
core   +1 more source

TME/NIR Dual‐Responsive Zinc‐Based Targeted Nanoagonist for Multimodal Amplification of STING‐Mediated Cancer Immunotherapy

Advanced Science, EarlyView.
A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu, Jiawei Wang, Wei Zhang, Zhixuan Wu, Jing Chen, Yujing He, Xiyue Duan, Yaoting He, Xin Xin, Haoyi Xiang, Yijing Wang, Chengwei Wu, Yang Yi, Qing Meng, Yuqian Qiao, Kui Cheng, Xiaojun Long, Zhangfa Song   +17 more
wiley   +1 more source

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Advanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan, Changwei Yuan, Mei Zhang, Yifan Zuo, Elena Papaleo, Yue Shi, Yuan Liang, Xuesong Li, Hongzhao Li, Weimin Ci   +20 more
wiley   +1 more source

Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model

Chinese Medical Journal, 2015
Background: Alemtuzumab has been used in organ transplantation and a variety of hematologic malignancies (especially for the treatment of B-cell chronic lymphocytic leukemia).
Lin-Lin Qu, Ya-Qing Lyu, Hai-Tao Jiang, Ting Shan, Jing-Bin Zhang, Qiu-Rong Li, Jie-Shou Li   +6 more
doaj   +1 more source